

From: Tom McAllister <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 2/15/2017 4:54:06 AM
Subject: Doors open to RNA Therapeutics next week | Join MHRA, Silence Therapeutics, GSK, Roche, AstraZeneca

RNA Therapeutics 2017

SMi's 8th Annual Conference: 22nd & 23rd February | Interactive Workshop: 21st February
Copthorne Tara Hotel, London UK

[Last chance to register](#) | [Agenda](#) | [Get in touch](#)

ATTENDEE LIST ONLINE!

Latest attendee's: Centre de Biophysique moléculaire, Admedus Immunotherapies, Merck Sharp & Dohme, UCB BioPharma SPRL, NOF Corporation, Silence Therapeutics. [View list](#)
Please note registration will be **closing soon**. Secure your attendance today
at www.therapeutics-rna.com

"RNA therapeutics, including recent exciting advancements in RNA-based vaccines, have the potential to be game-changing technologies. This conference will bring together thought leaders from across the technology area and a great opportunity to cross fertilize"
– Jeffrey Ulmer, Head of Preclinical Research & Development, GSK

Doors open to RNA Therapeutics in just one week!

Dear Mr Tony Kester,

If you have not confirmed your attendance yet there is still time to secure your place at **RNA Therapeutics 2017** when it returns to Central London next week.

Now running for almost a decade, RNA Therapeutics has firmly become established as the industry's premier platform for updates on **targeted drug delivery systems, networking and industry developments**, don't miss the chance to book your place before registration closes. [Sign up](#).

Event highlights:

Attendees from across the world. Nations confirmed to attend include:

Australia, Belgium, Denmark, Germany, Ireland, Israel, Italy, Japan, Netherlands, Switzerland, Ukraine, United Kingdom and USA. [View attendee list](#)

MHRA Keynote Address: Don't miss our exclusive **MHRA keynote** on RNAi therapy regulations. As well as providing a detailed overview of the regulatory landscape, the talk given by **John Johnston**, Clinical Assessor in the Biologicals and Biotechnology Unit, will offer guidance on requirements and reporting clinical data. [Visit the website for details](#)

Over 17 presentations from a mix of leading industry players and scientific pioneers such as **Imperial College London, GSK, AstraZeneca, Novartis, Roche, BioNTech AG, Silence Seed, Quark Pharmaceuticals, Exicure** and more.

[Download a brochure](#) to take a look at the full conference programme and speaker line up for 2017.

Pre-conference interactive workshop carefully selected to bring you hands on training and complement the topics covered in the conference agenda.

The need for functional delivery of RNAi effectors to target cells is a primary problem that is holding back the field of RNAi therapeutics. Nanoparticles, molecular conjugates, and other delivery technologies have their place but are they really working well enough? If not why not? And if they do appear to be working, what will it actually take to realise clinical success?

Hosted by **Andrew Miller**, Professor of Organic Chemistry & Chemical Biology at **Imperial College London**, the workshop on **Precision Nano-Therapeutics: Minding The Gap In Delivery From Preclinical Studies To Clinical Success**, will help attendees appreciate the magnitude of the gap that must be bridged between academic-preclinical studies and the needs of the pharma industrial for success in RNAi therapeutics.

[View workshop details](#)

Get involved:

For your **last chance to register**, visit www.therapeutics-rna.com

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For delegate enquiries, **group bookings** or **VIP packages** to attend all 3 days, contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk

www.therapeutics-rna.com

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>